Bisacchi Gregory S, Slusarchyk William A, Bolton Scott A, Hartl Karen S, Jacobs Glenn, Mathur Arvind, Meng Wei, Ogletree Martin L, Pi Zulan, Sutton James C, Treuner Uwe, Zahler Robert, Zhao Guohua, Seiler Steven M
The Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA.
Bioorg Med Chem Lett. 2004 May 3;14(9):2227-31. doi: 10.1016/j.bmcl.2004.02.011.
Azetidinones such as BMS-363131 (2) and BMS-363130 (3), which contain a guanidine group in the C-3 side chain were previously shown to be very potent inhibitors of human tryptase with high selectivity versus other serine proteases, including trypsin. In this letter, we describe the discovery of a number of potent azetidinone tryptase inhibitors in which the guanidine moiety at the ring C-3 position is replaced with primary or secondary amine or aminopyridine functionality. In particular, BMS-354326 (4) is a highly potent tryptase inhibitor (IC(50)=1.8 nM), which has excellent selectivity against trypsin and most other related serine proteases.
氮杂环丁烷酮类化合物,如BMS-363131(2)和BMS-363130(3),其C-3侧链含有胍基,先前已证明它们是非常有效的人组织蛋白酶抑制剂,对包括胰蛋白酶在内的其他丝氨酸蛋白酶具有高选择性。在这封信中,我们描述了一系列有效的氮杂环丁烷酮类组织蛋白酶抑制剂的发现,其中环C-3位置的胍基部分被伯胺、仲胺或氨基吡啶官能团取代。特别是,BMS-354326(4)是一种高效的组织蛋白酶抑制剂(IC50 = 1.8 nM),对胰蛋白酶和大多数其他相关丝氨酸蛋白酶具有优异的选择性。